BD resumes U.S. ChloraPrep shipments after FDA warning letter prompts added release testing
Share
Listen to the news
BD resumes U.S. ChloraPrep shipments after FDA warning letter prompts added release testing
  • BD resumed U.S. shipments of ChloraPrep following a voluntary ship hold tied to additional final release testing.
  • The ship hold was triggered by extra release testing implemented in response to an FDA warning letter for the El Paso manufacturing facility.
  • Additional final release testing has been acceptable so far, with no patient safety signals reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-039005), on May 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending